What the FDA actually says about compounded peptides
9 min read · Uplevel editorial
You've read something online that says compounded peptides are "banned by the FDA." You've also read something that says the FDA has nothing to do with compounded medications and it's all perfectly legal. Both of those things feel partially true and you can't reconcile them into a single coherent picture. The confusion is understandable. It's also fixable — because the FDA's actual position is precise, if you read it carefully rather than reading it through the filter of whoever was alarmed or reassured enough to write about it.
Start with what the FDA actually does. The FDA's primary regulatory function in the pharmaceutical space is the review and approval of finished drug products. When a pharmaceutical company wants to market a drug, it submits a new drug application — an NDA — that includes clinical trial data, safety data, manufacturing information, and labeling. The FDA reviews that package and either approves the drug for specific indicated uses or it doesn't. The drug that comes out of that process is an FDA-approved finished pharmaceutical product. It has a specific formulation, a specific manufacturer, and a specific approved indication.
Compounded medications are categorically different. They are not submitted for NDA review. They are not approved as finished drugs. A compounded peptide — whether it's sermorelin, NAD+, BPC-157, or any other compounded compound — has not gone through the FDA's new drug approval process. This is not a gray area or a technicality. It is the definition of what a compounded medication is. Compounding exists in a different legal framework, codified in Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act, which describes the conditions under which pharmacies may prepare medications outside the standard drug approval process.
The important thing the FDA is not saying: it is not claiming that compounded peptides are dangerous. It is not claiming that they don't work. It is saying that it has not evaluated the specific batches of compounded peptides that reach patients for safety, effectiveness, or quality — because the approval framework doesn't apply to them. The responsibility for quality in a compounded product rests with the pharmacy that prepared it and with the oversight systems — state pharmacy boards for 503A pharmacies, FDA facility inspections for 503B outsourcing facilities — that govern those pharmacies. The FDA's position is a description of the regulatory framework, not a condemnation of the products.
This distinction matters because the two most common misreadings of the FDA's position run in opposite directions. The first misreading is: "the FDA hasn't approved it, so it's unsafe or illegal." This is wrong. Compounding is legal within its framework. Pharmacies that operate lawfully under 503A or 503B are not doing something illicit. The absence of FDA approval is a feature of the category, not a finding about the specific product. The second misreading is: "compounded medications aren't FDA-regulated, so there's no oversight and anything goes." This is also wrong. 503A pharmacies operate under state pharmacy board oversight. 503B outsourcing facilities are subject to FDA cGMP standards and inspection. Both frameworks impose real accountability. Neither eliminates all risk, but neither is operating in a regulatory vacuum.
What the FDA does actively regulate in the compounding space is which substances can be legally compounded. This is where the regulatory complexity becomes most practical. For 503B outsourcing facilities — pharmacies that compound in large batches without patient-specific prescriptions — the FDA maintains lists of bulk drug substances that may or may not be compounded. These lists are the result of a formal nomination and evaluation process. The categories matter: Category 1 means the substance is being evaluated for possible inclusion on the list that permits 503B compounding. Category 2 means there is insufficient publicly available information to conclude the substance is safe and effective for use in compounding by outsourcing facilities — and therefore, 503B outsourcing facilities should not use it. The categories are specific to 503B. They do not directly govern what 503A pharmacies may do, which is a separate and more complex regulatory question.
BPC-157 is the most discussed example of a peptide that has been directly affected by this evaluation process. In 2023, the FDA placed BPC-157 on Category 2 of the 503B bulk drug substances list. The determination was that there is not enough safety data in the publicly available scientific literature to support its use by outsourcing facilities. What this means in practical terms: 503B outsourcing facilities should not be compounding BPC-157. What this does not automatically determine: whether 503A pharmacies can legally compound BPC-157 under a valid patient-specific prescription is a question that involves different legal analysis, different regulatory authority, and different facts. The 503A and 503B frameworks are separate sections of the law. The Category 2 determination is specific to the 503B evaluation process. As of 2023 and into the following period, the regulatory landscape for BPC-157 at 503A pharmacies remained a subject of active legal and regulatory attention, and the situation continued to evolve. If you have a prescription for BPC-157, your prescribing provider and your pharmacy are the right people to consult about current availability and compliance in your jurisdiction.
This kind of fluidity — where the regulatory status of a compound changes as the FDA works through its evaluation process — is not unique to BPC-157. It reflects the ongoing nature of FDA oversight in the compounding space. The agency is actively reviewing bulk drug substances and updating its lists. A compound that was compoundable last year may be placed in a different category this year. A compound under evaluation may be clarified in either direction. Staying current on this means working with a prescribing provider who tracks these changes, not relying on what a forum post said twelve months ago.
The FDA's role in the quality of individual compounded batches is worth being precise about. For a 503A-compounded product, the FDA does not inspect or approve the individual batch before it reaches you. The state pharmacy board licenses and oversees the pharmacy. The quality of the product — its identity, potency, purity, sterility, endotoxin level — is the pharmacy's responsibility, and the evidence for quality is in the pharmacy's own documentation and third-party testing. A certificate of analysis from an accredited independent laboratory is the record that a legitimate compounding pharmacy produces. The FDA's non-involvement in individual batch approval is why that documentation is the primary evidence of quality for the end user. It's not a workaround — it's how the regulatory framework is designed to work.
For 503B outsourcing facilities, the FDA's involvement is more direct. These facilities must comply with current Good Manufacturing Practice standards. The FDA inspects them. They must report adverse events. The documentation burden is higher and the manufacturing standards are closer to those of conventional pharmaceutical manufacturers. That additional federal oversight is part of what 503B facilities offer in exchange for the ability to compound in larger batches without patient-specific prescriptions.
None of this means compounded peptides are equivalent to FDA-approved drugs. They aren't. The FDA approval process — the NDA pathway — involves clinical trials, efficacy data, and a systematic review that compounding pharmacies do not go through. That's a real difference. Whether that difference matters for your specific situation, under a prescription from a provider who has reviewed your case and sourced from a pharmacy with strong quality systems, is a clinical and personal decision — not a purely regulatory one.
What regulators are actually doing when they place a compound in Category 2 or issue guidance on compounding is attempting to apply a safety framework to a sector that operates outside the standard approval pathway. The FDA is not the enemy of compounding. It is not indifferent to it either. It is attempting to draw lines between what is accountable and what is not, in a space where the accountability mechanisms are distributed across state boards, federal inspection programs, pharmacy quality systems, and prescriber responsibility. Those lines are real and they change. Understanding where they are — accurately, without the distortion of either alarm or dismissal — is what lets you make informed decisions about the medications you're being prescribed.
The precise, neutral version of the FDA's position on compounded peptides is this: they are not FDA-approved, meaning FDA has not evaluated them for safety, efficacy, or quality as finished drugs; they are legally compounded under specific frameworks with specific conditions; the compounding pharmacy and the state or federal oversight system applicable to it are responsible for quality; and the agency is actively working through an evaluation process that is changing what certain types of pharmacies may legally compound. That's the full picture. Everything shorter than that leaves something out.